Sofie Derijcke

884 citations
19 papers · 734 · 1 hit paper · h-index 8

Impact in

  • Oncology top 5%
    • Cancer Immunotherapy and Biomarkers
    • Cancer survivorship and care
    • Lung Cancer Research Studies
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Lung Cancer Treatments and Mutations 6
    • Lung Cancer Diagnosis and Treatment 2
    • Cancer-related cognitive impairment studies 1
    • Cancer Immunotherapy and Biomarkers 3
    • Cancer survivorship and care 2

Sofie Derijcke

18 papers receiving 728 citations

Sofie Derijcke's Hit Papers

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 2018 · 498 citations
4980+2+5Years since publication100200300400

Peers

Sofie Derijcke
Comparison fields: 5 of 48
  • Oncology 407
  • Pulmonary and Respiratory Medicine 360
  • Geriatrics and Gerontology 10
  • Cancer Research 26
  • Internal Medicine 4
Replace Aaron M. Chapman with:
Aaron M. Chapman United States
Giovanni Bruno Vicario Italy
Tomomi Kashiwada Japan
J. Casal Spain
Eriko Miyawaki Japan
Francisco Aparisi Spain
Ornella Cantale Italy
Taichi Miyawaki Japan
Rosaria Gallucci Italy
Diana Mendus United States
Sofie Derijcke relative to Aaron M. Chapman United States Aaron M. Chapman's profile →
Citations per field
00.5×2×3×4×
Aaron M. Chapman · 1×
Citations per year

Countries citing papers authored by Sofie Derijcke

Since Specialization
Citations

This map shows the geographic impact of Sofie Derijcke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofie Derijcke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofie Derijcke more than expected).

Fields of papers citing papers by Sofie Derijcke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofie Derijcke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofie Derijcke. The network helps show where Sofie Derijcke may publish in the future.

Co-authors

The 25 scholars most cited alongside Sofie Derijcke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sofie Derijcke Line = papers co-authored together Sofie Derijcke links everyone, so they are left out of the graph.

All Works

19 of 19 papers shown
#Work
1
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Hit paper breakdown →
2018498
2 202277
3 201741
4 202025
5 201422
6 201818
7 201715
8 201711
9 20105
10 20215
11 20204
12 20214
13 20224
14
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
20091
15 20131
16 20221
17 20231
18 20251
19 20240

About Sofie Derijcke

Sofie Derijcke is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Immunology, Geriatrics and Gerontology and Conservation, having authored 19 papers that have together received 734 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer survivorship and care (2 papers), Lung Cancer Diagnosis and Treatment (2 papers), Immunotherapy and Immune Responses (2 papers), Hearing Loss and Rehabilitation (1 paper), Cancer-related cognitive impairment studies (1 paper) and Dementia and Cognitive Impairment Research (1 paper). The work is most often cited by research in Oncology (407 citations), Pulmonary and Respiratory Medicine (360 citations), Geriatrics and Gerontology (10 citations), Cancer Research (26 citations) and Internal Medicine (4 citations). Sofie Derijcke has collaborated with scholars based in Belgium, United Kingdom and Switzerland. Frequent co-authors include Johan Vansteenkiste, Veerle F.M. Surmont, Philippe L. Vergauwe, Hans Pottel, Annelies Janssens, Philip R. Debruyne, Jan P. van Meerbeeck, Tom Boterberg, Koen Van Eygen and D. Galdermans. Their work appears in journals such as Annals of Oncology, Clinical Lung Cancer, Psycho-Oncology, Respiratory Medicine and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact